GlassScriptPhysician profile
Amanda Reynolds
NPI 1952785222
$8,819.20
in general payments reported to CMS, 2019-2025
42 companies · $1,885 in 2025
The $1,885 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,725 · 2022: $1,774 · 2023: $1,813 · 2024: $1,622 · 2025: $1,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,319.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,229.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,095.02 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,024.84 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $849.90 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $790.84 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $732.86 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $444.17 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $247.02 | 2021-2025 | |
| Amgen INC. | $228.61 | 2021-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $228.54 | 2021-2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $201.10 | 2021-2024 | Yupelri |
| Axsome Therapeutics, INC. | $191.13 | 2023-2025 | Auvelity |
| Abbott Laboratories | $158.01 | 2021-2025 | Freestyle Libre, Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $139.11 | 2022-2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $121.92 | 2021-2024 | Verquvo, Belsomra, Steglatro |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Reynolds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.